Lupin Ltd announced that it has received a tentative approval from the US Food and Drug Administration (FDA) to market a generic version of the Prezista tablets, which are used for the treatment of HIV-1 infections. The generic version of the Janssen Products’ Prezista is the AB-rated generic equivalent of the original drug, the company said. Prezista tablets have annual sales of $12 billion in the US, Lupin added. Lupin would market the tablets in strengths of 75 mg, 150 mg, 300 mg, 400 mg, 600 mg and 800 mg. Business Line
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…
Nagpur, April 03, 2024: HCG Cancer Center Nagpur has launched a one-of-a-kind indigenous Asia`s first…